uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Recruiting now

Conditions studied: Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis

In brief

The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.

Key facts

Study ID

NCT05874921

Run by

UroGen Pharma Ltd.

People needed

400

Starts

2023-11-17

Expected to finish

2028-01-01

Last updated by the study team

2025-02-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults >18 years old and capable of giving informed consent.
• Diagnosis of UTUC.
• Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).

You may not qualify if…

• Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia).
• Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020).
• Pregnancy or lactation.
• Unable to comply with protocol requirements (for prospective data capture).
• Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).

Where it is running

• Providence St. Johns Health Center — Santa Monica, California, United States (enrolling)
• University of Florida — Gainesville, Florida, United States (enrolling)
• Mount Sinai Medical Center of Florida, Inc. — Miami, Florida, United States (enrolling)
• H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. — Tampa, Florida, United States (enrolling)
• Northwestern University — Chicago, Illinois, United States (enrolling)
• Indiana University — Indianapolis, Indiana, United States (enrolling)
• The State University of Iowa — Iowa City, Iowa, United States (enrolling)
• Chesapeake Urology — Baltimore, Maryland, United States (enrolling)
• Johns Hopkins Medical Center — Baltimore, Maryland, United States (enrolling)
• Mass General Hospital (MGH) — Boston, Massachusetts, United States (enrolling)
• The Brigham and Womens Hospital — Boston, Massachusetts, United States (enrolling)
• University of Michigan — Ann Arbor, Michigan, United States (enrolling)
• University of Missouri — Columbia, Missouri, United States (enrolling)
• Rutgers — New Brunswick, New Jersey, United States (enrolling)
• The Feinstein Institutes for Medical Research — Lake Success, New York, United States (enrolling)
• NYU Grossman School of Medicine — New York, New York, United States (enrolling)
• SUNY Upstate — Syracuse, New York, United States (enrolling)
• The University of North Carolina Chapel Hill — Chapel Hill, North Carolina, United States (enrolling)
• Ohio State University — Columbus, Ohio, United States (enrolling)
• Medical University of South Carolina — Charleston, South Carolina, United States (enrolling)
• UT Southwestern Medical Center — Dallas, Texas, United States (enrolling)
• The University of Texas M.D. Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.